117 related articles for article (PubMed ID: 27352067)
1. Does ponatinib cross the blood-brain barrier?
Abid MB; De Mel S
Br J Haematol; 2017 Nov; 179(3):497-498. PubMed ID: 27352067
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
[TBL] [Abstract][Full Text] [Related]
5. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
[TBL] [Abstract][Full Text] [Related]
6. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
7. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
8. T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.
Wang D; Pan H; Wang Y
Leuk Lymphoma; 2017 Jul; 58(7):1733-1735. PubMed ID: 27813432
[No Abstract] [Full Text] [Related]
9. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Menna P; De Grazia U; Marchesi F; Minotti G; Salvatorelli E
Chemotherapy; 2020; 65(1-2):35-41. PubMed ID: 32829325
[TBL] [Abstract][Full Text] [Related]
10. Success is built on failures: tackling the challenge of ponatinib failure.
Hiwase D; Ross D
Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
[No Abstract] [Full Text] [Related]
11. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
Thomas X
Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
[No Abstract] [Full Text] [Related]
12. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Shah NP
Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
[No Abstract] [Full Text] [Related]
13. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
14. Leukemia cutis with lymphoglandular bodies: a clue to acute lymphoblastic leukemia cutis.
Obiozor C; Ganguly S; Fraga GR
Dermatol Online J; 2015 Aug; 21(8):. PubMed ID: 26437164
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib for chronic myeloid leukemia.
Goldman JM
N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
[No Abstract] [Full Text] [Related]
17. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
18. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
Andrews C; Lipton J
Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
[No Abstract] [Full Text] [Related]
19. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
Abumiya M; Takahashi N; Yoshioka T; Kameoka Y; Miura M
J Clin Pharm Ther; 2021 Feb; 46(1):219-222. PubMed ID: 32985698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]